Long-term Safety with the SYNERGY Stent System
* In a landmark analysis at 24 hours.
† Current guidelines recommend that dual anti-platelet therapy (DAPT) with aspirin and an ADP receptor antagonist be continued for a minimum of 12-months following drug-eluting stent (DES) percutaneous coronary intervention (PCI).
1 Presented by D. Kereiakes, MD at ACC 2016.
2 Meredith, I, AM, MBBS, PhD. PCR 2016. Only the “full dose” SYNERGY Stent results are shown.
3 James, S. Adapted from presentation at TCT 2015.
SYNERGY Stent offers peace of mind knowing the polymer is fully absorbed between three and four months.1
Long-term data shows promising results with ZERO ARC definite/probable stent thrombosis and exceptionally low target lesion revascularization out to five years.
Five-Year Results: 0% ARC Definite/Probable ST and 1.1% TLR2
Presented by Ian T. Meredith AM, MBBS, PhD, PCR 2016. Only the “full dose” SYNERGY Stent results are shown.
All Target Vessel MI were NQWMI for both the SYNERGY and PROMUS Element Stents
*One NQWMI in the SYNERGY group was periprocedural. The remaining 2 NQWMI in the SYNERGY arm were considered unrelated to the study device: one at day 347 due to anemia and a major GI bleed, and one at day 364 subsequent to respiratory failure in a patient with severe COPD – enzymes were checked indicating that a NQWMI had occurred. The one death was of an unknown cause at day 472 and adjudicated as a Cardiac Death. Safety Population. All p-values are >0.05.